본문 바로가기
KERD
논문KCI 등재

Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study

Yan Zhang|Ruyan Zhang|Xiaoran Liu|Guohong Song|Huiping Li
대한암학회 (Korean Cancer Association)|2024.07|Cancer Research and Treatment|제56권 제3호|pp. 795-801|DOI 10.4143/crt.2023.1151

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Trastuzumab biosimilarHLX02PertuzumabMetastatic breast cancerHER2-positive
주제분류의학일반

초록

Purpose This study aims to evaluate the efficacy and safety of trastuzumab biosimilar (HLX02) in combination with pertuzumab and chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) after progression of trastuzumab. Materials and Methods In this prospective, single-arm, phase II study, patients with HER2-positive MBC after progression of trastuzumab received pertuzuamb, HLX02, and chemotherapy in Beijing Cancer Hospital from March 2020 to December 2022. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. The study was registered with ClinicalTrials.gov (NCT05188495). Results A total of 45 patients were included in this study. Twelve patients (26.7%) were treated in second-line and 33 patients (73.3%) were in third-line and later setting. Eighty percent and 15.5% patients had previously received pyrotinib/lapatinib and T-DM1, respectively. With a median follow-up of 24.4 months (range, 1.2 to 43.9 months), the median PFS was 7.6 months (95% confidence interval, 4.3 to 10.9), OS was not reached, the ORR was 31.1%, and DCR was 91.1%. The treatment was well tolerated. Conclusion The combination of trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy exhibited promising efficacy and a favorable safety profile as second- and beyond-line treatment in HER2-positive MBC.

Abstract

Purpose This study aims to evaluate the efficacy and safety of trastuzumab biosimilar (HLX02) in combination with pertuzumab and chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC) after progression of trastuzumab. Materials and Methods In this prospective, single-arm, phase II study, patients with HER2-positive MBC after progression of trastuzumab received pertuzuamb, HLX02, and chemotherapy in Beijing Cancer Hospital from March 2020 to December 2022. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. The study was registered with ClinicalTrials.gov (NCT05188495). Results A total of 45 patients were included in this study. Twelve patients (26.7%) were treated in second-line and 33 patients (73.3%) were in third-line and later setting. Eighty percent and 15.5% patients had previously received pyrotinib/lapatinib and T-DM1, respectively. With a median follow-up of 24.4 months (range, 1.2 to 43.9 months), the median PFS was 7.6 months (95% confidence interval, 4.3 to 10.9), OS was not reached, the ORR was 31.1%, and DCR was 91.1%. The treatment was well tolerated. Conclusion The combination of trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy exhibited promising efficacy and a favorable safety profile as second- and beyond-line treatment in HER2-positive MBC.

참고문헌 (25)

  1. Swain SM, "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA study) : overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study", Lancet Oncol, 14, pp.461~471 (2013)
  2. Xu B, "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer(PUFFIN) : final analysis of a phase III, randomized, double-blind, placebo-controlled study", Breast Cancer Res Treat, 197, pp.503~513 (2023)
  3. Swain SM, "Targeting HER2-positive breast cancer : advances and future directions", Nat Rev Drug Discov, 22, pp.101~126 (2023)
  4. Tapia M, "Clinical impact of new treatment strategies for HER2-positive metastatic breast cancer patients with resistance to classical anti-HER therapies", Cancers(Basel), 15, pp.4522~ (2023)
  5. Cardoso F, "5th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 5)", Ann Oncol, 31, pp.1623~1649 (2020)
  6. Extra JM, "Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients : the observational Hermine study", Oncologist, 15, pp.799~809 (2010)
  7. von Minckwitz G, "Trastuzumab beyond progression : overall survival analysis of the GBG 26", BIG 3-05 phase III study in HER2-positive breast cancer, 2011, pp.47, 2273~2281
  8. Iyengar NM, "Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer : a phase 2 clinical trial", JAMA Netw Open, 2, pp.e1916211~ (2019)
  9. Dang C, "Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer", J Clin Oncol, 33, pp.442~447 (2015)
  10. Yamamoto Y, "Pertuzumab retreatment for HER2-positive advanced breast cancer : a randomized, open-label phase III study(PRECIOUS)", Cancer Sci, 113, pp.3169~3179 (2022)
  11. Yamamoto Y, "A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced", metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy : the Japan Breast Cancer Research Group-M05 PRECIOUS study, 2018, pp.48, 855~859
  12. Urruticoechea A, "Final overall survival(OS)analysis of PHEREXA : a randomized phase III trial of trastuzumab(H)plus capecitabine(X)+", -pertuzumab(P)in patients with HER2-positive metastatic breast cancer(MBC)who experienced disease progression during or after H-based therapy, 2018, pp.36(15 Suppl), 1013~
  13. Urruticoechea A, "PHEREXA : a phase III study of trastuzumab(H)+ capecitabine(X)± pertuzumab(P)for patients(pts)who progressed during", after one line of H-based therapy in the HER2-positive metastatic breast cancer(MBC)setting, 2016, pp.34(15 Suppl), 504~
  14. Qian Y, "Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer : a retrospective single-armed cohort study in China", Ann Transl Med, 10, pp.877~ (2022)
  15. Krop IE, "Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer(TH3RESA) : a randomised, open-label, phase 3 trial", Lancet Oncol, 15, pp.689~699 (2014)
  16. Rugo HS, "Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer : a phase 3 randomized clinical trial", JAMA Oncol, 7, pp.573~584 (2021)
  17. "Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial", BMJ, 383, pp.p2665~ (2023)
  18. Cortes J, "Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer", N Engl J Med, 386, pp.1143~1154 (2022)
  19. Dieras V, "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA) : a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial", Lancet Oncol, 18, pp.732~742 (2017)
  20. Welslau M, "Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine(T-DM1)versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer", Cancer, 120, pp.642~651 (2014)
  21. Xu B, "Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer(PHOEBE) : a multicentre, open-label, randomised, controlled, phase 3 trial", Lancet Oncol, 22, pp.351~360 (2021)
  22. Geyer CE, "Lapatinib plus capecitabine for HER2-positive advanced breast cancer", N Engl J Med, 355, pp.2733~2743 (2006)
  23. Saura C, "Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens : phase III NALA trial", J Clin Oncol, 38, pp.3138~3149 (2020)
  24. Modi S, "Trastuzumab deruxtecan in previously treated HER2-positive breast cancer", N Engl J Med, 382, pp.610~621 (2020)
  25. Iihara H, "Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan : an open-label, randomized, and multicenter exploratory phase 2 Study", J Cancer, 14, pp.2644~2654 (2023)

관련 논문AI추천

Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+ Advanced Breast Cancer After Trastuzumab Failure (PROVE): A Prospective Phase 2 StudyChunfang Hao, Jie Zhang, Lan Zhang, Li Zhang, Shufen Li, Wenjing Meng, Xiaodong Liu, Xu Wang, Yehui Shi, Zhongsheng Tong대한암학회 · Cancer Research and Treatment2025 · 제57권 제2호Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-arm, Prospective StudyCong Xue, Fei Xu, Jiajia Huang, Jianhao Huang, Jingmin Zhang, Kuikui Jiang, Liang Li, Meiting Chen, Qianyi Lu, Qiufan Zheng, Ruoxi Hong, Shusen Wang, Wen Xia, Xin An, Xiwen Bi, Yanxia Shi, Zhongyu Yuan대한암학회 · Cancer Research and Treatment2024 · 제56권 제2호Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer김지연, 김홍식, 박연희, 안진석, 이민상, 이용표, 임영혁대한암학회 · Cancer Research and Treatment2022 · 제54권 제4호Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant ChemotherapyJingyang Zhang, Mingda Zhu, Minhao Lv, Xiuchun Chen, Youzhao Ma, Zhenzhen Liu대한암학회 · Cancer Research and Treatment2023 · 제55권 제4호Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysisCongcong Ji, Depei Huang, Feilong Zhao, Jian Li, Jifang Gong, Lin Shen, Ting Xu, Xiaotian Zhang, Xicheng Wang, Yanyan Li, Ying Xin, Yuezong Bai, Yu Sun, Zhenghang Wang대한암학회 · Cancer Research and Treatment2023 · 제55권 제2호Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain MetastasisBiyun Wang, Jian Zhang, Jun Cao, Leiping Wang, Mingxi Lin, Sheng Zhang, Xichun Hu, Ying Lin, Yiqun Du, Zhonghua Tao대한암학회 · Cancer Research and Treatment2020 · 제52권 제4호

이 간행물의 다른 논문 (26건)

Editor’s Note on Recent Journal Impact Factor of Cancer Research and Treatment안용찬pp. 699-699HER2-low Breast Cancer: Now and in the Future강소라, 김성배pp. 700-720Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP박세훈, 유창훈, 조영미, 김인호, 김형돈, 김한상, 이지은, 정현애, 이혜승, 김시현, 남수정, 김진원, 윤홍석, 이성영, 김지형, 김지현, 이충근, 김한조, 차용준, 김완섭, 전상훈, 심효섭, 임선민, 이인희, 김지훈, 홍숙희, 윤진아, 이아원, 천재경, 박소연, 김미소, 나기용, 윤선옥, 장기택, 박인근, 윤신교, 정재호pp. 721-742Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid TumorsSunil Sharma, 홍용상, 김정은, 류민희, 최창민, 김태원, 류백열, 강윤구, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Wernerpp. 743-750Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time BiasWanchen Zhai, Yun Fan, Ying Yu, Hui Li, Ning Chen, Sizhe Yu, Wanji Shenpp. 751-764
원문 보기